T3	Subject 40 48	children
T4	Treatment 29 36	TMP-SMX
T5	Speculation_cue 85 96	potentially
T6	Effect 97 146	life-threatening, immunemediated hypersensitivity
T8	Age 40 48	children
T9	Drug 29 36	TMP-SMX
T10	Severity_cue 97 113	life-threatening
T7	Adverse_event 147 155	reaction
E1	Adverse_event:T7 
A1	Severity E1 High